<DOC>
	<DOCNO>NCT00132756</DOCNO>
	<brief_summary>The purpose research study test safety , tolerability , effectiveness drug combination Doxil ( doxorubicin ) estramustine use treat prostate cancer resistant hormone chemotherapy type call taxanes . The primary hypothesis reduce measurable disease prostate-specific antigen ( PSA ) level least 50 % baseline .</brief_summary>
	<brief_title>Liposomal Doxorubicin Estramustine Phosphate : Study Taxane Resistant , Hormone Refractory Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>Patients must histologically confirm advanced , prostate cancer Patients must evaluable disease may evaluate PSA measurement . Patients must hormone refractory define protocol . Patients must taxane refractory define protocol . Patients prior chemotherapy taxane estramustine phosphate . Patients may prior radiation therapy ( RT ) &gt; /= 4 week since completion . Patients bisphosphonates may include . Patients must least 18 year age old . Patients must ability speak understand English . Patients must ECOG performance status 2 less . Patients must adequate bone marrow function : platelet &gt; 100,000 cells/mm3 ; hemoglobin &gt; 9.0 g/dL ; absolute neutrophil count ( ANC ) &gt; 1,000 cells/mm3 . Patients must adequate renal function : creatinine &lt; 2.5 mg/dL . Patients must adequate liver function . Ejection fraction &gt; 50 % within 42 day first dose study drug . Ability complete McGillMelzack Pain Intensity Scale . Patients unstable medical condition liver , renal dysfunction , blood clot heart disease . History hypersensitivity doxorubicin . History class II cardiac disease evidence congestive heart failure . RT within past 4 week study entry radiopharmaceutical within past 8 week study entry . Prior malignancy within past 5 year except nonmelanotic skin cancer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Hormone Refractory</keyword>
	<keyword>Taxane Refractory</keyword>
</DOC>